Trending
Prev Story
Next Story

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC World •
November 18, 2026 • 02:02 PM
• By Annika Kim Constantino,Brandon Gomez
2
2 reads 0 reactions

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

Hims & Hers Health on Wednesday said it will offer five formulations of peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform, all of which are not approved by regulators.

Even as it announced the new products, Hims & Hers acknowledged it has more to learn about how best to use the peptides and how effective they are — underscoring the uncertainty surrounding the growing space.

The new offerings come after the federal government eased restrictions on compounding certain unapproved peptides, which are short chains of amino ​acids. Those products have exploded in popularity among fitness and longevity enthusiasts who attest that they help with muscle growth, rapid injury recovery and anti-aging, even though most lack evidence from robust human trials.

Hims in late October launched an early access list for the upcoming peptide offerings, and more than 10,000 people signed up within 15 days, a company spokesperson said in a statement.

None of the company's specific compounded products are approved by the Food and Drug Administration. But Hims said they are authorized by law and formulated by pharmacies "that adhere to rigorous quality standards and are licensed and inspected by state boards of pharmacy."

The products include compounded formulations of sermorelin, a peptide that stimulates growth-hormone release and is marketed for recovery, body composition and anti-aging; glutathione, a peptide promoted ‌for anti-aging and athletic recovery; and nicotinamide adenine dinucleotide, or NAD+, a coenzyme that plays a role in cellular metabolism.

The company will also offer compounded versions of vitamin B-12, a vitamin needed to make red blood cells, build DNA, and maintain healthy nerve function, and L-carnitine, an amino acid derivative that helps the body turn fat into energy. The FDA has approved certain prescription forms of both peptides for established medical uses, primarily for diagnosed deficiencies in those compounds.

Hims said it plans to add more peptides and therapies made in the U.S. over time. That includes BPC-157, an unapproved peptide derived from a protein found in human gastric juice that is marketed for healing processes. The company also aims to introduce another unapproved peptide called TB-500, which is derived from a naturally occurring protein in the body and is marketed for broader, systemic soft-tissue recovery and flexibility. Most of the research on both has been conducted in animals, not humans.

To receive the products, members on the Hims platform will start with an assessment of health history and goals with a licensed provider trained in peptide therapies, who can tailor a personalized plan to their needs, if appropriate.

The company said it intends to use its communication platform to check in with patients and ensure they are seeing desired results.

"If they're not, we need to do something about it," Dr. Anant Vinjamoori, Hims chief medical officer, told CNBC. "We need to, you know, adjust the dose when that's appropriate, or in some cases consider other compounds that's maybe a better fit. And of course, there will also be cases when we need to refer people to other care options."

However, Vinjamoori said there's still uncertainty over how to best use the peptides.

"We don't have all of this data that we're used to having with compounds like this," he said. "We have the opportunity to get it right, and I think we see that as our responsibility with a company of our size, our skill, and resources to really lead."

Vinjamoori added that people who have serious illnesses, such as cardiovascular disease, liver disease and kidney disease, will not be candidates for the compounds for now.

Meanwhile, Andrew Huberman, a well known neuroscientist, podcaster and Stanford University School of Medicine professor who recently joined Hims' board of directors, in a statement called compounds "real medical treatments, not just a wellness trend." He said Hims provides safe access through "trusted sourcing and physician oversight."

But health experts raised concerns about the broader mainstream marketing of peptides in the U.S. and accessing them on telehealth platforms.

"With peptides, I think you have to view them the same way you would view any drug that hasn't been rigorously tested," said Joshua Kritzer, a chemistry professor at Tufts University. "Without actual testing, all you have is anecdotal information, and that's just not enough information to put a substance in your body."

Kritzer said the lack of large clinical trials means researchers can't rule out potentially serious, rare complications from peptides — the kinds of risks that have led regulators to reject or pull otherwise effective drugs from the market after they underwent comprehensive testing in humans.

Without that testing, it's also unclear how telehealth firms, physicians and pharmacies can make decisions about what doses patients should take, said Paul Knoepfler, a cell biology and human anatomy professor at UC Davis Health. While some people rely on anecdotal data from real peptide users, "the dosing for these products really has not been established," he added.

Knoepfler said one risk is that injecting too much of a synthetic peptide into patients could trigger "weird immune responses that are really bad for one's health" because the body might recognize it as foreign.

"With the peptides, it's very loosey-goosey," Knoepfler told CNBC. "How does one even know what would be the effective amount for whatever you're hoping it will do, and what amount would have more risks?"

But he said the more contact patients can have with physicians around taking a compounded peptide, the better. Providers, including those tied to telehealth firms, should make sure patients are well-informed about the possible risks and unknowns of a given product and consider their preexisting conditions, cancer history and other medications, Knoepfler said.

That appears to be consistent with the approach Hims & Hers is taking. The company says patients who use the peptide and longevity products can also use its Care+ offering, which pairs treatment with ongoing support. That includes twice-a-year lab testing to track their progress and the ability to message providers trained in peptide therapy around the clock with any questions.

Still, Kritzer argued that having a doctor who only knows a patient from online, essentially mail-order platforms or websites "is not enough supervision to put you on a prescription medication," especially an unapproved one.

Hims' ability to legally sell some of these peptides stems from a major shift in federal oversight by the Health and Human Services Department. It issued a policy in October that says the Food and Drug Administration will not take enforcement action against licensed pharmacies, federal facilities or physicians that compound and dispense six unapproved peptides while formal rules are reviewed.

In practice, that means these pharmacies and other firms can now offer them, even though the peptides aren't yet on the FDA's official list of ingredients compounding pharmacies are allowed to make. It does not translate to formal approval of the specific peptides.

The policy followed a 2023 decision by the Biden administration where the FDA restricted compounding pharmacies from producing popular peptide formulations due to safety, impurity and immune-reaction concerns.

HHS Secretary ​Robert F. Kennedy Jr. has supported broader access to peptides, calling himself a "big fan" of the treatments and arguing that restrictions were driving Americans to potentially unsafe products from overseas. Kennedy has previously described using BPC-157 to treat a muscle injury.

The announcement also comes after Hims in February 2025 acquired a California-based peptide manufacturing facility equipped with advanced peptide synthesizers.

The evidence for peptide efficacy varies by compound.

A 2026 systematic review screening 113 studies, including both small trials on humans along with rodent research, found zero eligible clinical outcome trials proving that administering IV or intramuscular NAD+ improves anti-aging, energy, or wellness endpoints in humans.

There is some evidence for specific uses of certain peptides, such as potential weight loss. A review of 37 L-carnitine trials found participants lost about 2.7 pounds on average, though that analysis does not demonstrate that a compounded injection works the same way.

Meanwhile, vitamin B-12 injections are most commonly used to help people with a diagnosed deficiency rather than preventative care. U.S. survey data shows only 3.6% of adults are B-12 deficient.

Glutathione's evidence is thin, too. IV injections of it are widely marketed for skin whitening, yet not FDA-approved for this purpose.

A small study published in the Journal of Pakistan Association of Dermatologists evaluating IV glutathione showed that the treatment is "not very effective" for skin-lightening, and that it loses efficacy with time.

The FDA also said in August that it received reports of at least 30 patients who experienced adverse events after they received compounded IV glutathione alone or in combination with other ingredients from different compounding pharmacies.

All of the glutathione tied to the reports were from the same wholesale distributor and was labeled as dietary supplement grade, which is not an appropriate ingredient to make injectable drugs. Two of the Texas pharmacies conducted recalls related to elevated endotoxin levels in their glutathione injectable drugs.

These studies and reports don't speak to how Hims' exact combination will perform, but they do highlight the current limits on data studying the treatments and the questions surrounding them.

Prev Swipe Story Next

Related Stories

World News
Build #2612